


THE CLAIMS


A listing of the claims are as follows.

1. (currently amended) An anthraquinone compound of the general formula I or a salt thereof



I

in which R¹ is at the 4 position and is to R⁴ are each selected from the group consisting of H, C₁₋₄ alkyl, X¹, -NHR^ON (R⁵)₂ in which R^O is a C₁₋₁₂ alkanediyl and each R⁵ is H or optionally substituted C₁₋₄ alkyl, and a group of formula II




in which at least one of R⁶, R⁷ and R⁸ is selected from X², and X² substituted C₁₋₄ alkyl and any others are H or C₁₋₄ alkyl; R⁹ is selected from H, C₁₋₄ alkyl, X² and X² substituted C₁₋₄ alkyl;

m is 0 or 1;

n is 1 or 2;

X¹ is a halogen atom, a hydroxyl group, a C₁₋₆ alkoxyl group, an aryloxy group or an acyloxy group; and

R² is at the 1 position and is selected from H, -NHR^ON (R⁵)₂ in which R^O is a C₁₋₁₂ alkanediyl and each R⁵ is H or optionally substituted C₁₋₄ alkyl, and a group of formula II



in which at least one of R⁶, R⁷ and R⁸ is selected from X², and X² substituted C₁₋₄ alkyl and any others are H or C₁₋₄ alkyl; R⁹ is selected from H, C₁₋₄ alkyl, X² and X² substituted C₁₋₄ alkyl;

m is 0 or 1;

n is 1 or 2;

R³ is at the 5 position and is H or OH;

R⁴ is at the 8 position and is H or OH;

X² is a halogen atom, a hydroxyl group, a C₁₋₆ alkoxy group, an aryloxy group or an acyloxy group or another nucleofugal leaving group;

provided that at least one of R¹ to R⁴ is a group of formula II.

2. (Original) A compound according to claim 1 in which R¹ and R² are each a group of formula II.

3. (Original) A compound according to claim 1 in which R¹ is a group of formula II and R² is NHR^ON(R⁵)₂.

4. (Original) A compound according to claim 3 in which each R⁵ is the same and is H or CH₃.

5-6. (Canceled)

7. (Original) A compound according to claim 6 in which R³ and R⁴ are both hydroxyl and are substituted at positions 5 and 8 in the anthraquinone ring system.

8. (Original) A compound according to claim 6 in which R³ and R⁴ are both H.

9. (Previously Presented) A compound according to claim 1, in which m is 1.

10. (Previously Presented) A compound according to claim 1, in which m is 0.

11. (Previously Presented) A compound according to claim 1, in which n is 2.

12. (Previously Presented) A compound according to claim 1, in which X² is a halogen atom or a leaving group.

13. (Original) A compound according to claim 12, in which X² is chlorine.

14. (Previously Presented) A compound according to claim 1, in which either
i) R⁶ is CH₂X³ and R⁷ is H; or
ii) R⁶ is H and R⁷ is X³.

15. (Original) A compound according to claim 14 in which R⁶ is CH₂X³ and R⁷ is H.

16. (Original) A compound according to claim 15 in which n is 2 and R⁹ is CH₂X³ in which X³ is the same as X³ in R⁶.

17. (Canceled)

18. (Previously Presented) A composition comprising a compound according to claim 9 and an excipient.

19. (Original) A composition according to claim 18 which is a pharmaceutical composition and in which the excipient is a pharmaceutically acceptable excipient.

20-39. (Canceled)

40. (Currently Amended) A composition comprising a compound according to claim 12 and an excipient.

41-43. (Canceled)

44. (New) A compound selected from the group consisting of:

1-{[(2-Dimethylamino)ethyl]amino}-4-{[2-(3-hydroxypiperidin-1-yl)ethyl]amino}-anthracene-9,10-dione;

1,4-Bis-{[2-(3-hydroxypiperidin-1-yl)ethyl]-amino}-anthracene-9,10-dione;

1,4-Bis-{[2-(3-hydroxymethylpiperidine-1-yl)ethyl]amino}-5,8-dihydroxy-anthracene-9,10-dione;

1,4-Bis-{[2-(3-hydroxymethylpiperidine-1-yl)ethyl]amino}-anthracene-9,10-dione;

1-[(2-Dimethylamino)ethylamino]-4-[2-(3-hydroxymethyl-piperidin-1-yl)ethylamino]-5,8-dihydroxy-anthracene-9,10-dione;

1-[(2-Dimethylamino)ethylamino]-4-[2-(3-hydroxypiperidin-1-yl)-ethylamino]-5,8-dihydroxy-anthracene-9,10-dione;

1,4-Bis-{[2-(2-hydroxymethylpiperidin-1-yl)ethyl]amino}-5,8-dihydroxy-anthracene-9,10-dione;

1-{[(2-Dimethylamino)ethyl]amino}-4-{[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]amino}-5,8-dihydroxy-anthracene-9,10-dione;

1-{[(2-Dimethylamino)ethyl]amino}-4-{[2-(4-hydroxypiperidin-1-yl)ethyl]amino}-anthracene-9,10-dione;

1,4-Bis-{[2-(3-hydroxypyrrrolidin-1-yl)ethyl]amino}-5,8-dihydroxy-anthracene-9,10-dione;

1,4-Bis-{[2-(4-hydroxypiperidin-1-yl)ethyl]amino}-5,8-dihydroxy-anthracene-9,10-dione;

1-{[(2-Dimethylamino)ethyl]amino}-4-{[2-(4-hydroxypyrrrolidin-1-yl)ethyl]amino}-5,8-dihydroxy-anthracene-9,10-dione;

1-{[(2-Dimethylamino)ethyl]amino}-4-{[-2-(2-hydroxymethylpiperidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1,4-Bis- {[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(2,6-Dihydroxymethylpiperidin-1-yl)ethyl]amino}-4- {[(2-Dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; and
1- {[2-(2-Hydroxymethylpyrrolidin-1-yl)ethyl]amino}-anthracene-9,10-dione.

45. (New) A compound selected from the group consisting of:

1- {[2-(3-Chloropiperidin-1-yl)ethyl]amino}-4- {[(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(4-Chloropiperidin-1-yl)ethyl]amino}-4- {[(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(2-Chloromethylpyrrolidin-1-yl)ethyl]-amino}-4- {[(2-Dimethylamino)ethyl] amino} - 5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(3-Chloropyrrolidin-1-yl)ethyl]amino}-4- {[(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(3-Chloropiperidin-1-yl)ethyl]amino}-4- {[(2-dimethylamino)ethyl]amino}-anthracene-9,10-dione;

1- {[2-(2-Chloromethylpiperidin-1-yl)ethyl]amino}-4- {[(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(2-Chloromethylpiperidin-1-yl)ethyl]-(amino)}-4- {[(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(2,6-Dichloromethylpiperidin-1-yl)ethyl]-amino}-4- {[(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; and

1- {[2-(2-chloromethylpyrrolidin-1-yl)ethyl]amino}-anthracene-9,10-dione.

46. (New) A compound selected from the group consisting of:

1,4-Bis- {[2-(2-chloromethylpyrrolidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1,4-Bis- {[2-(3-chloromethylpiperidin-1-yl)ethyl]amino}-anthracene-9,10-dione;

1,4-Bis- {[2-(3-chloromethylpiperidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; and

1,4-Bis- {[2-(2-chloromethylpiperidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione.

47. (New) The compound:

1- {[2-(2-Hydroxymethylpyrrolidin-1-yl-*N*-oxide)ethyl]amino}-4- {[(2-dimethylamino-*N*-oxide)ethyl]amino}-5,8-dihydroxy-anthracene-9,10-dione.

48. (New) A compound selected from the group consisting of:

1- {[2-(3-Chloropiperidin-1-yl-*N*-oxide)ethyl]amino}-4- {[(2-dimethylamino-*N*-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(4-Chloropiperidin-1-yl-*N*-oxide)ethyl]amino}-4- {[(2-dimethylamino-*N*-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; and

1- {[2-(2-Chloromethylpyrrolidin-1-yl-*N*-oxide)ethyl]amino}-4- {[(2-dimethylamino-*N*-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione.

49. (New) The compound:

1,4-Bis- {[2-(2-chloromethylpiperidin-1-yl-*N*-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione.

50. (New) A composition comprising a compound and an excipient, wherein the compound is according to claim 10.